Results from a controlled clinical trial from China on the use of hydroxy chloroquine as a treatment for Covid-19 have shown no significant differences in health outcomes between the control group and patients who received the experimental drug. 

Thirty patients hospitalized for Covid-19 participated in the trial. Fifteen were treated with 400mg of chloroquine for five days and fifteen received standard supportive care. A week after the treatments started both groups were evaluated and results showed that no measurable difference in the progression of the disease. There are still important lessons to draw from the results.

Read full on article on Forbes

Originally published on Forbes (March 25, 2020)